1-5 of 5
Jonathan C. Strefford
Close
Sort by
Journal Articles

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

Giorgia Chiodin, Samantha Drennan, Enrica A. Martino, Laura Ondrisova, Isla Henderson, Luis del Rio, Ian Tracy, Annalisa D’Avola, Helen Parker, Silvia Bonfiglio, Lydia Scarfò, Lesley-Ann Sutton, Jonathan C. Strefford, Jade Forster, Oliver Brake, Kathleen N. Potter, Benjamin Sale, Stuart Lanham, Marek Mraz, Paolo Ghia, Freda K. Stevenson, Francesco Forconi
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5494–5504.
https://doi.org/10.1182/bloodadvances.2021006659
Published: 2022
Includes: Supplemental data
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials

Clinical Trials & Observations
Tomasz K. Wojdacz, Harindra E. Amarasinghe, Latha Kadalayil, Alice Beattie, Jade Forster, Stuart J. Blakemore, Helen Parker, Dean Bryant, Marta Larrayoz, Ruth Clifford, Pauline Robbe, Zadie A. Davis, Monica Else, Dena R. Howard, Basile Stamatopoulos, Andrew J. Steele, Richard Rosenquist, Andrew Collins, Andrew R. Pettitt, Peter Hillmen, Christoph Plass, Anna Schuh, Daniel Catovsky, David G. Oscier, Matthew J. J. Rose-Zerilli, Christopher C. Oakes, Jonathan C. Strefford
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2474–2481.
https://doi.org/10.1182/bloodadvances.2019000237
Published: 2019
Includes: Supplemental data
Journal Articles

CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up

Helen Parker, Neil Robert McIver-Brown, Zadie A. Davis, Marina Parry, Matthew J. J. Rose-Zerilli, Aliki Xochelli, Jane Gibson, Renata Walewska, Jonathan C. Strefford, David G. Oscier
Journal: Blood Advances
Blood Adv (2018) 2 (10): 1116–1119.
https://doi.org/10.1182/bloodadvances.2018019760
Published: 2018
Includes: Supplemental data